The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma
JHEP Rep. 2021 May 11;3(4):100305. doi: 10.1016/j.jhepr.2021.100305.eCollection 2021 Aug.
Zobair M Younossi123, Linda Henry4
Author information
1Center for Liver Disease and Department of Medicine, Inova Fairfax Medical Campus, Falls Church, VA, United States.
2Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, United States.
3Medical Service Line. Inova Health Systems, Falls Church, VA, United States.
4Center for Outcomes Research in Liver Diseases, Washington DC, United States.
Abstract
The prevalence of hepatocellular carcinoma (HCC) is increasing worldwide, whereas that of most other cancers is decreasing. Non-alcoholic fatty liver disease (NAFLD), which has increased with the epidemics of obesity and type 2 diabetes, increases the risk of HCC. Interestingly, NAFLD-associated HCC can develop in patients with or without cirrhosis. A lack of awareness about NAFLD-related HCC has led to delays in diagnosis. Therefore, a large number of patients with HCC are diagnosed with advanced-stage HCC with low 5-year survival. In this context, increasing awareness of NAFLD and NAFLD-related HCC may lead to earlier diagnosis and more effective interventions.